Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR +1.76%71 EV-to-FCF is 183.70 as of Aug. 30, 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 71/100 and a GF Value™ of kr2.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 412 Medical Devices & Instruments companies, Medclair AB ranks worse than 92.48% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medclair AB's Enterprise Value is kr263.60 Mil.
Medclair AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was kr1.44 Mil. Therefore, Medclair AB's EV-to-FCF for today is 183.70.
The historical rank and industry rank for Medclair AB's EV-to-FCF or its related term are showing as below:
NGM:MCLR'
s EV-to-FCF Range Over the Past 10 Years
Min: -279.79 Med: -20.89 Max: 195.28
Current: 183.7
During the past 11 years, the highest EV-to-FCF of Medclair AB was 195.28. The lowest was -279.79. And the median was -20.89.
NGM:MCLR's EV-to-FCF is ranked worse than 92.48% of 412
companies
in the Medical Devices & Instruments industry
Industry Median: 24.755
vs NGM:MCLR: 183.70
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medclair AB's PE Ratio (TTM) for today is calculated as:
Medclair AB's share price for today is kr2.89.
Medclair AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medclair AB EV-to-FCF Related Terms
Medclair AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Medclair AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medclair AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Medclair AB's EV-to-FCF falls into.
Medclair AB's current Enterprise Value is kr263.60 Mil.
Medclair AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a EV-to-FCF of 183.70 as of Aug. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medclair AB and its competitors. According to the industry distribution chart, Medclair AB ranks #381 out of 412 companies in the Medical Devices & Instruments industry, placing it in the top 92.5%.
Is Medclair AB's EV-to-FCF too high?
Medclair AB's current EV-to-FCF is 183.70. The Medical Devices & Instruments industry median EV-to-FCF is 24.76. Medclair AB's value of 183.70 is 642.1% above this industry median. Based on the distribution chart, Medclair AB ranks #381 out of 412 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medclair AB has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #381 out of 412 companies for EV-to-FCF. This places Medclair AB in the lower half of its industry. The industry median EV-to-FCF is 24.76. Medclair AB's value of 183.70 is 642.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.76, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current EV-to-FCF of 183.70 is 642.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current EV-to-FCF is 183.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.21, compared to a current price of kr2.89 — trading 30.8% above its estimated fair value. The current EV-to-FCF is 183.70 and 642.1% above the Medical Devices & Instruments industry median of 24.76. Medclair AB's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current EV-to-FCF is 183.70 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.89 is trading 30.8% above its estimated GF Value™ of kr2.21.
GuruFocus considers Medclair AB to be Significantly Overvalued.
Key valuation signals for NGM:MCLR:
EV-to-FCF: 183.70
GF Value™: kr2.21 vs. price of kr2.89 (30.8% above fair value)
Industry Position: 642.1% above the Medical Devices & Instruments median (#381 of 412)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
71GF Score
Get the complete analysis for NGM:MCLR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
